fucosylation when added directly to cell culture media. This approach allows biomanufacturers to tune antibody fucosylation levels using existing cell lines and bioreactor processes without significantly affecting cell growth or antibody titers. Carbaform Biosciences targets applications in oncology and other therapeutic areas where improved antibody effector function and targeting of low-density antigens are important. The company provides tools intended for research and biopharmaceutical manufacturing workflows, aiming to integrate into established upstream production processes.